Premium
Plasma proteins predict conversion to dementia from prodromal disease
Author(s) -
Hye Abdul,
RiddochContreras Joanna,
Baird Alison L.,
Ashton Nicholas J.,
Bazenet Chantal,
Leung Rufina,
Westman Eric,
Simmons Andrew,
Dobson Richard,
Sattlecker Martina,
Lupton Michelle,
Lun Katie,
Keohane Aoife,
Ward Malcolm,
Pike Ian,
Zucht Hans Dieter,
Pepin Danielle,
Zheng Wei,
Tunnicliffe Alan,
Richardson Jill,
Gauthier Serge,
Soininen Hilkka,
Kłoszewska Iwona,
Mecocci Patrizia,
Tsolaki Magda,
Vellas Bruno,
Lovestone Simon
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.1749
Subject(s) - dementia , disease , medicine , neuroimaging , oncology , alzheimer's disease , cognitive impairment , clinical trial , cognition , bioinformatics , psychiatry , biology
Background The study aimed to validate previously discovered plasma biomarkers associated with AD, using a design based on imaging measures as surrogate for disease severity and assess their prognostic value in predicting conversion to dementia. Methods Three multicenter cohorts of cognitively healthy elderly, mild cognitive impairment (MCI), and AD participants with standardized clinical assessments and structural neuroimaging measures were used. Twenty‐six candidate proteins were quantified in 1148 subjects using multiplex (xMAP) assays. Results Sixteen proteins correlated with disease severity and cognitive decline. Strongest associations were in the MCI group with a panel of 10 proteins predicting progression to AD (accuracy 87%, sensitivity 85%, and specificity 88%). Conclusions We have identified 10 plasma proteins strongly associated with disease severity and disease progression. Such markers may be useful for patient selection for clinical trials and assessment of patients with predisease subjective memory complaints.